Influence of serum HMGB1 level on the incidence of respiratory Distress syndrome in neonates.

The aim of this study was to analyse the correlation between high mobility group protein B1 (HMGB1) and neonatal respiratory distress syndrome (NDS), and to provide a theoretical basis for its diagnosis and prognosis. Sixty cases of neonates with respiratory distress syndrome were selected and designated as a survival group (36 cases) and a death group (24 cases) according to their prognosis. Sixty healthy neonates were also selected and designated as the control group. Peripheral venous blood and related clinical data of the neonates were collected 12-24 h after birth. Enzyme-linked immunosorbent assay (ELISA) was used to detect the level of HMGB1 in the sera of the two groups. SPSS 17 software was used for statistical analysis of the experimental data. The test results showed that the serum HMGB1 levels of those in the study group were significantly higher than those of the control group, and the difference was statistically significant (P less than 0.05); the serum HMGB1 levels of those in the death group was significantly higher than those in the survival group, and the difference was statistically significant (P less than 0.05). Serum HMGB1 level predicts the area under curve (AUC) value of NRDS as 0.872. A serum HMGB1 level of 625.2198pg/mL represents the best boundary value for predicting NRDS. The serum HMGB1 level predicts the AUC of death from NRDS children as 0.912, and a level of 786.7643pg/mL represents the best boundary value for predicting patient death. In conclusion, the level of HMGB1 in the sera of newborns can better predict the occurrence and death of NRDS, and can therefore be considered as a marker for its diagnosis, evaluation and prognosis.